mangafodipir


Also found in: Wikipedia.

mangafodipir

 [mang″gah-fo´dĭ-pir]
a contrast-enhancing agent used to improve the images obtained in magnetic resonance imaging (MRI) of hepatic lesions; administered intravenously as the trisodium salt.
Mentioned in ?
References in periodicals archive ?
Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague-Dawley rats.
Kim, "MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents," American Journal of Roentgenology, vol.
Pajaud et al., "Pretreatment with mangafodipir improves liver graft tolerance to ischemia/ reperfusion injury in rat," PloS One, vol.
Detection of Liver Metastases from Adenocarcinoma of the Colon and Pancreas: Comparison of Mangafodipir Trisodium - Enhanced Liver MRI and Whole - Body FDG PET.
PledPharma has restarted recruitment on a clinical trial of mangafodipir in treatment outcomes during angioplasty.
The efficacy of PledOx in reducing serious side-effects of oxaliplatin has been compared with that of another PLED-derivative, mangafodipir, in a preclinical model.
One of the earliest HPB agents available was Mangafodipir trisodium.
Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst, 2006, 98, 236-244.
5.) Contrast agents used for MR imaging of the liver are gadopentetate dimeglumine (GDTPA) and mangafodipir trisodium.
mangafodipir, manganese dipyridoxyl diphosphate, MnDPDP) or nonchelated forms (e.g.
The older of the 2 agents is mangafodipir trisodium (TESLASCAN, GE Healthcare, Chalfont St.
The liver-specific contrast agent mangafodipir trisodium (Teslascan, GE Healthcare, Princeton, NJ) is excreted via the biliary system and T1W MRI after injection of this agent may be useful in the diagnosis of a bile leak.